MacroGenics Revenue and Competitors

Location

$165.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MacroGenics's estimated annual revenue is currently $116M per year.(i)
  • MacroGenics received $23.6M in venture funding in April 2017.
  • MacroGenics's estimated revenue per employee is $302,846
  • MacroGenics's total funding is $165.9M.
  • MacroGenics's current valuation is $884.6M. (January 2022)

Employee Data

  • MacroGenics has 383 Employees.(i)
  • MacroGenics grew their employee count by -6% last year.

MacroGenics's People

NameTitleEmail/Phone
1
Executive Director Business DevelopmentReveal Email/Phone
2
VPReveal Email/Phone
3
VPReveal Email/Phone
4
General CounselReveal Email/Phone
5
VP, Market Access & ReimbursementReveal Email/Phone
6
Head IT Quality and ComplianceReveal Email/Phone
7
VP, Executive Director, Senior Director, Director ManufacturingReveal Email/Phone
8
VP, Facilities and EngineeringReveal Email/Phone
9
VP, ContractsReveal Email/Phone
10
VP & ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15M204-6%N/AN/A
Add Company

What Is MacroGenics?

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics most advanced program is margetuximab, an Fc-optimized monoclonal antibody that targets HER2, and is being investigated in the SOPHIA study, a Phase 3, randomized, multi-center clinical trial in patients with metastatic breast cancer.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$165.9M

Total Funding

383

Number of Employees

$116M

Revenue (est)

-6%

Employee Growth %

$884.6M

Valuation

N/A

Accelerator

MacroGenics News

2022-04-19 - MacroGenics (NASDAQ:MGNX) Stock Rating Lowered by ...

MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its...

2022-04-17 - MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call - Benzinga

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the...

2022-04-06 - MacroGenics (NASDAQ:MGNX) Lifted to Hold at Zacks ...

MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its...

2021-10-26 - MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial resu ...

2021-09-16 - MacroGenics : Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021 (Form 8-K)

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021 •21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility b ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$80M38824%N/A
#2
$125.7M3960%N/A
#3
$93.1M4101%$638.2M
#4
$64.1M42729%N/A
#5
$136.9M44775%N/A

MacroGenics Funding

DateAmountRoundLead InvestorsReference
2001-09-25$13.5MAArticle
2002-06-07$12.6MA+Article
2003-10-31$5.0MStrategic InvestmenGenzymeArticle
2004-10-18$30.5MBAlta Partners, TPG VenturesArticle
2006-02-07$40.0MThirdArticle
2006-05-18$45.0MUndisclosedMultipleArticle
2008-09-26$25.0MD-2Nextech VentureArticle
2014-02-12$UndisclosedUndisclosedBofA Merrill LynchArticle
2015-07-16$130.4MUndisclosedMorgan StanleyArticle
2017-04-28$23.6MUndisclosedArticle